NERV · Minerva Neurosciences, Inc.
AI read · Neutral
The AI's read
The transcript says the C19 study is ongoing and uses hopeful language about roluperidone. It includes no new study findings or reported change to the study, so it gives no clear reason to change the company's outlook.